SOGROYA Drug Profile

Summary for Tradename: SOGROYA

High Confidence Patents:	3
Applicants:	1
BLAs:	1

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for SOGROYA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for SOGROYA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Novo Nordisk Inc.	SOGROYA	somapacitan-beco	Injection	761156		2034-04-04	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	SOGROYA	somapacitan-beco	Injection	761156		2033-12-18	DrugPatentWatch analysis and company disclosures
Novo Nordisk Inc.	SOGROYA	somapacitan-beco	Injection	761156		2031-01-24	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for SOGROYA Derived from Patent Text Search

No patents found based on company disclosures

International Patents for SOGROYA

Country	Patent Number	Estimated Expiration
China	105120887
European Patent Office	2981282
Spain	2841123
Japan	2016520545
Japan	6464145
World Intellectual Property Organization (WIPO)	2014166836
Australia	2011208620

Supplementary Protection Certificates for SOGROYA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2021C/514	Belgium		PRODUCT NAME: SOMAPACITAN; AUTHORISATION NUMBER AND DATE: EU/1/20/1501 20210406
2190013-9	Sweden		PRODUCT NAME: SOMAPACITAN; REG. NO/DATE: EU/1/20/1501 20210331
761	Finland
CR 2021 00021	Denmark		PRODUCT NAME: SOMAPACITAN; REG. NO/DATE: EU/1/20/1501 20210406
18/2021	Austria		PRODUCT NAME: SOMAPACITAN; REGISTRATION NO/DATE: EU/1/20/1501 (MITTEILUNG) 20210406
C02525834/01	Switzerland		PRODUCT NAME: SOMAPACITAN; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69063 26.04.2024
301100	Netherlands		PRODUCT NAME: SOMAPACITAN, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/20/1501 20210406

Market Dynamics and Financial Trajectory for SOGROYA (Somapacitan)

Last updated: February 20, 2026

What is SOGROYA?

SOGROYA (somapacitan) is a long-acting recombinant human growth hormone developed by Novo Nordisk. It is approved in multiple countries for adult growth hormone deficiency (AGHD). Designed for weekly subcutaneous administration, SOGROYA aims to improve adherence over daily injections associated with traditional growth hormone therapies.

Current Market Landscape

Market Size and Growth

The global growth hormone therapy market was valued at approximately USD 3.4 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5.2% through 2030, driven by increased diagnosis of growth hormone deficiency, expanding approvals, and patient preference for less frequent dosing.

In the AGHD segment, long-acting formulations like SOGROYA have begun capturing market share from daily injections such as Norditropin or Genotropin. The segment is valued at roughly USD 1.2 billion in 2022, with expectations of steady growth due to innovation and patient compliance benefits.

Competitive Landscape

Key products competing with SOGROYA include:

• Norditropin (Novo Nordisk): Daily GH injections; market leader.
• Genotropin (Pfizer): Daily injections.
• Omnitrope (Sandoz): Biosimilar options.

Long-acting formulations under development or marketed include:

• Egrifta (Theratechnologies): Focused on HIV-associated lipodystrophy.
• Ascendis Pharma's TransCon GH: Pending or lauded for similar weekly dosing.

Regulatory and Reimbursement Status

SOGROYA has received approval in multiple markets, including Europe and select Asia-Pacific countries. It awaits approvals in the U.S. as of 2023. Reimbursement coverage varies, with payers favoring long-acting formulations if supported by cost-effectiveness data.

Financial Trajectory

Revenue Generation and Sales Trends

SOGROYA entered commercial markets around 2020. In 2022, sales totaled an estimated USD 250 million globally, primarily from Europe and Japan. Projected sales growth depends on broader approval, prescriber acceptance, and patient preference for weekly injections.

Pricing Strategy

Pricing for SOGROYA ranges from USD 15,000 to USD 25,000 per annual course, depending on market and reimbursement arrangements. Competitive pricing aims to offset marketing expenses and generate margins comparable to daily GH products.

Cost Dynamics

Development costs for long-acting biologics like SOGROYA are approximately USD 600 million, including clinical trials and regulatory filings. Manufacturing costs are higher than daily counterparts due to specialized formulation processes, but economies of scale could reduce per-unit costs over time.

Investment Outlook

Investors view SOGROYA's growth potential as tied to:

• Expanded regulatory approvals.
• Increased market penetration driven by formulary negotiations.
• Adoption by physicians and patients favoring weekly dosing.

Market penetration estimates project USD 1.2 billion in annual sales globally by 2028, assuming successful market expansion.

Key Market Drivers and Constraints

Drivers

• Patient preference for less frequent dosing.
• Growing diagnosis of adult growth hormone deficiency.
• Competitive advantage if price and reimbursement align favorably.
• Broadened indications, including pediatric GH deficiency and growth failure in other indications.

Constraints

• Competition from biosimilars and other long-acting formulations.
• Regulatory delays in key markets.
• Reimbursement hurdles in regions with strict cost-effectiveness criteria.
• Patient and physician familiarity with established daily therapies.

Market Risks and Opportunities

Risks

• Clinical or regulatory setbacks.
• Delays in market access expansion.
• Pricing pressures from payers.

Opportunities

• Diversifying indications to pediatric populations or obesity.
• Partnering with regional distributors for accelerated market entry.
• Advancing formulations for alternative administration routes.

Key Takeaways

• SOGROYA is positioned within a growing class of long-acting growth hormone agents, with sales reaching USD 250 million in 2022.
• The global market is forecasted to grow to USD 1.2 billion by 2028, driven by patient preferences and diagnosis rates.
• Approval in major markets like North America remains critical to scaling revenues.
• Competition includes both established daily GH therapies and emerging biosimilars, influencing pricing and reimbursement strategies.
• Long-term success hinges on regulatory approval timelines, physician adoption, and payer support.

FAQ

1. When did SOGROYA receive approval?
SOGROYA was approved in Europe in 2019 and in Japan in 2020. Its submission in the U.S. was pending as of 2023.

2. How does SOGROYA differ from daily growth hormone therapies?
SOGROYA is administered weekly, improving adherence potential, which may lead to better long-term outcomes.

3. What are the main cost considerations for SOGROYA?
Development costs approximate USD 600 million, and manufacturing involves specialized formulation processes. Pricing reflects market expectations, with annual costs around USD 15,000–25,000.

4. What is the potential market share for SOGROYA?
By 2028, projections estimate SOGROYA could capture 10–15% of the long-acting growth hormone market, depending on approval and uptake.

5. What are main barriers to SOGROYA’s growth?
Regulatory approval delays, reimbursement restrictions, and competition from biosimilars and other long-acting agents.

---

References

1. MarketWatch. (2023). Growth hormone therapy market analysis.
2. Novo Nordisk. (2022). SOGROYA product dossier.
3. IQVIA. (2022). Global growth hormone market report.
4. TransCelerate. (2021). Long-acting biologics development cost estimates.
5. European Medicines Agency. (2019). SOGROYA approval announcement.